| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56571SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1327SS | |||
| Azide and BSA Free | NBP2-80626 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-71663SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-77913-25ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-64895SS | |||
| Azide and BSA Free | NBP2-80651 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-48337SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| IHC-Prediluted | NBP2-44808 | |||
| Azide and BSA Free | NBP2-34689-0.1mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-36561SS | |||
| Azide and BSA Free | NBP2-80818 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-724SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-725SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-78039SS | |||
| Azide and BSA Free | NBP2-80921 | |||
![Western Blot: TLR3 Antibody [NB100-56571] - Myocardial infarction (MI) increased TLR3 expression and its physical association with Trif in mouse myocardium. Heart samples were taken from infarct area at 4 weeks after MI. (A) and (B) show mRNA and protein levels of TLR3 in sham and MI hearts. n = 4 mice/group. Data are means +/- S.D. AP < 0.01 versus sham. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/jcmm.13328) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR3-Antibody-Western-Blot-NB100-56571-img0009.jpg "<b>Biological Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: TLR3 Antibody [NB100-56571] - Myocardial infarction (MI) increased TLR3 expression and its physical association with Trif in mouse myocardium. Heart samples were taken from infarct area at 4 weeks after MI. (A) and (B) show mRNA and protein levels of TLR3 in sham and MI hearts. n = 4 mice/group. Data are means +/- S.D. AP < 0.01 versus sham. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/jcmm.13328) licensed under a CC-BY license.")
![<b>Biological Strategies Validation and Orthogonal Strategies Validation.</b>Immunohistochemistry-Frozen: TLR3 Antibody [NB100-56571] - Frozen mouse eye tissue sections stained with TLR3, a retinal pigment epithelium (RPE) marker and DAPI. Top panel: TLR3 (red) colocalized with the RPE (green) marker. Bottom panel: Tissue stained with isotype control (no TLR3 Ab), RPE and DAPI. Data courtesy of Kleinman et al.](http://images.novusbio.com/fullsize/TLR3-Antibody-Immunohistochemistry-Frozen-NB100-56571-img0002.jpg)
![Flow Cytometry: TLR3 Antibody [NB100-56571] - Analysis using the FITC conjugate of NB100-56571. Staining of TLR3 in Balb/c mouse splenocytes using this antibody at 1 ug/10^6 cells. Green represents rabbit IgG isotype control this antibody; red represents anti-TLR3 antibody.](http://images.novusbio.com/fullsize/TLR3-Antibody-Flow-Cytometry-NB100-56571-img0008.jpg)
![Western Blot: TLR3 Antibody [NB100-56571] - Analysis of TLR3 in mouse spleen tissue lysate using NB100-56571 at 2 ug/ml.](http://images.novusbio.com/fullsize/TLR3-Antibody-Western-Blot-NB100-56571-img0005.jpg)
![Immunohistochemistry: TLR3 Antibody [NB100-56571] - Pig lung poisoned through aspiration with gastric juice and organophosphate (dimethoate EC40) after 48 hours of IC ventilation. Image from verified customer review.](http://images.novusbio.com/fullsize/TLR3-Antibody-Immunohistochemistry-NB100-56571-img0006.jpg)
![Flow Cytometry: TLR3 Antibody [NB100-56571] - Intracellular flow analysis of TLR3 in Balb/c mouse splenocytes and mouse RAW cells using TLR3 antibody (red) and isotype control antibody (green) at 1 ug/10^6 cells.](http://images.novusbio.com/fullsize/TLR3-Antibody-Flow-Cytometry-NB100-56571-img0001.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TLR3 Antibody [NB100-56571] - siRNA was transfected at 50 nM for 48 hrs, and poly(I:C) was added at 100 ug/ml for 4 hrs before cell harvest. Negative control (NC) siRNA served as control. RNAiMAX transfection reagent was used in all the siRNA experiments. Panel shows the knockdown effects of siRNAs. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/jcmm.13328) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR3-Antibody-Knockdown-Validated-NB100-56571-img0010.jpg)
![Western Blot: TLR3 Antibody [NB100-56571] - Myocardial infarction (MI) increased TLR3 expression & its physical association with Trif in mouse myocardium. Heart samples were taken from infarct area at 4 weeks after MI. (A) & (B) show mRNA & protein levels of TLR3 in sham & MI hearts. n = 4 mice/group. Data are means ± S.D. AP < 0.01 versus sham. (C) Representative immunohistochemistry images of heart sections stained for TLR3 (brown colour). An isotype IgG control was performed to verify the specificity of TLR3 reactivity. (D) Lysates of heart tissue were immunoprecipitated with anti‐TLR3 antibodies (IP: TLR3), followed by SDS–PAGE & immunoblotting (IB) with indicated antibodies. IP with isotype IgG (IP: IgG) was performed as a control to exclude the non‐specific binding of antibodies to cellular proteins. Green arrows indicate non‐specific bands. The association between TLR3 & Trif, but not MyD88, was detectable in sham myocardium & was increased in infarct myocardium. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28945004), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56571_rabbit-polyclonal-tlr3-antibody-310202415523938.jpg)
![Western Blot: TLR3 Antibody [NB100-56571] - Myocardial infarction (MI) increased TLR3 expression & its physical association with Trif in mouse myocardium. Heart samples were taken from infarct area at 4 weeks after MI. (A) & (B) show mRNA & protein levels of TLR3 in sham & MI hearts. n = 4 mice/group. Data are means ± S.D. AP < 0.01 versus sham. (C) Representative immunohistochemistry images of heart sections stained for TLR3 (brown colour). An isotype IgG control was performed to verify the specificity of TLR3 reactivity. (D) Lysates of heart tissue were immunoprecipitated with anti‐TLR3 antibodies (IP: TLR3), followed by SDS–PAGE & immunoblotting (IB) with indicated antibodies. IP with isotype IgG (IP: IgG) was performed as a control to exclude the non‐specific binding of antibodies to cellular proteins. Green arrows indicate non‐specific bands. The association between TLR3 & Trif, but not MyD88, was detectable in sham myocardium & was increased in infarct myocardium. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28945004), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56571_rabbit-polyclonal-tlr3-antibody-3102024165731.jpg)
![Immunohistochemistry: TLR3 Antibody [NB100-56571] - Myocardial infarction (MI) increased TLR3 expression & its physical association with Trif in mouse myocardium. Heart samples were taken from infarct area at 4 weeks after MI. (A) & (B) show mRNA & protein levels of TLR3 in sham & MI hearts. n = 4 mice/group. Data are means ± S.D. AP < 0.01 versus sham. (C) Representative immunohistochemistry images of heart sections stained for TLR3 (brown colour). An isotype IgG control was performed to verify the specificity of TLR3 reactivity. (D) Lysates of heart tissue were immunoprecipitated with anti‐TLR3 antibodies (IP: TLR3), followed by SDS–PAGE & immunoblotting (IB) with indicated antibodies. IP with isotype IgG (IP: IgG) was performed as a control to exclude the non‐specific binding of antibodies to cellular proteins. Green arrows indicate non‐specific bands. The association between TLR3 & Trif, but not MyD88, was detectable in sham myocardium & was increased in infarct myocardium. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28945004), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56571_rabbit-polyclonal-tlr3-antibody-310202415535158.jpg)
![Western Blot: TLR3 Antibody [NB100-56571] - TLR3‐knockout (TLR3‐KO) attenuated cardiac autophagy induced by MI. The infarct & remote tissues were separately sampled from the left ventricle after 4 weeks of MI. Accordingly, anterior & posterior tissues of the left ventricle were sampled from sham hearts as controls. (A) Representative Western blot images & quantitative analyses of autophagy markers. n = 4–8/group. Quantitative data are fold changes of WT‐sham. aP < 0.05, AP < 0.01 versus respective WT‐sham; bP < 0.05, BP < 0.01 versus respective WT‐MI. (B) Representative electron microphotographs of ultrathin sections of resin‐embedded heart biopsies. Arrows indicate autophagic vacuoles. (C) Lysates of infarct tissue were immunoprecipitated (IP), followed by SDS–PAGE & immunoblotting (IB) with indicated antibodies. IP with isotype IgG served as a control. Green arrows indicate non‐specific bands. Representative images were taken from four independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28945004), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56571_rabbit-polyclonal-tlr3-antibody-310202415525214.jpg)
![Western Blot: TLR3 Antibody [NB100-56571] - A TLR3 agonist polyinosinic‐polycytidylic acid (poly(I:C)) induced autophagy in cultured cardiomyocytes through a TRIF‐dependent pathway. (A) Poly(I:C) increased autophagy markers in cultured H9c2 rat ventricular cells. (B) Poly(I:C) stimulated autophagosome formation but did not affect autophagic flux. Primary cultured neonatal rat ventricular myocytes (NRVMs) were transfected with a tandem mRFP‐GFP‐LC3 adenovirus for 24 hrs, followed by treatment with poly(I:C) (100 μg/ml, 4 hrs). Autophagosomes & autolysosomes were, respectively, visualized as yellow‐ & red‐only punctas under a confocal microscope. (C) An autophagic flux inhibitor chloroquine (CQ) induced accumulations of LC3‐II & p62/SQSTM1 proteins in H9c2 myocytes receiving poly(I:C) (100 μg/ml, 4 hrs). CQ was applied at 10 μM, immediately prior to poly(I:C). (D) Effects of indicated siRNA on poly(I:C)‐induced changes in autophagy markers in NRVMs. All the siRNAs were transfected at 50 nM for 48 hrs, & poly(I:C) was added at 100 μg/ml for 4 hrs before cell harvest. Negative control (NC) siRNA served as control. RNAiMAX transfection reagent was used in all the siRNA experiments. The upper panel shows the knockdown effects of siRNAs, & the lower panel shows representative Western blot images (presented from four independent experiments) & densitometry quantitative data (normalized into ‘fold of vehicle group’). All quantitative data are expressed as means ± S.D. aP < 0.05, AP < 0.01 versus vehicle; bP < 0.05, BP < 0.01 versus poly(I:C). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28945004), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56571_rabbit-polyclonal-tlr3-antibody-3102024168394.jpg)
![Immunohistochemistry: CD11b Antibody (M1/70.15) [NB600-1327] - Immunohistochemical analysis of frozen lymph node section using CD11b Antibody (M1/70.15) [NB600-1327] followed by staining with HRP-conjugated secondary antibody.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunohistochemistry-NB600-1327-img0012.jpg "Immunohistochemistry: CD11b Antibody (M1/70.15) [NB600-1327] - Immunohistochemical analysis of frozen lymph node section using CD11b Antibody (M1/70.15) [NB600-1327] followed by staining with HRP-conjugated secondary antibody.")
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) [NB600-1327] - Characterization of microglia cultures by multiple staining with CD11b Antibody (M1/70.15) [NB600-1327] (panels a. & c.) and anti GFAP (panels b & d). Nuclei appear blue due to 4',6-diamidino-2-phenylindole (DAPI) counter staining.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunocytochemistry-Immunofluorescence-NB600-1327-img0013.jpg)
![Flow Cytometry: CD11b Antibody (M1/70.15) [NB600-1327] - A surface stain was performed on Raw264.7 cells with CD11b (M1/70.15) Antibody [NB600-1327R] (blue) and a matched isotype control (orange), both conjugated to DyLight 550. Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Flow-Cytometry-NB600-1327-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) - BSA Free [NB600-1327] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody [M1/70.15] (NB600-1327) at 1ug/ml overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-BSA-Free-Immunocytochemistry-Immunofluorescence-NB600-1327-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) - BSA Free [NB600-1327] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody [M1/70.15] conjugated to Alexa Fluor 488 (NB600-1327AF488) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-BSA-Free-Immunocytochemistry-Immunofluorescence-NB600-1327-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) [NB600-1327] - Immunocytochemistry/Immunofluorescence (ICC/IF) analysis of RAW264.7 cells using CD11b antibody (M1/70.15) [NB600-1327] with Dylight 488 conjugated secondary (green). Nuclei and tubulin were stained with 4',6-diamidino-2-phenylindole (DAPI) (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunocytochemistry-Immunofluorescence-NB600-1327-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) [NB600-1327] - Immunocytochemical/Immunofluorescent staining in untreated and treated mouse microglia cells using CD11b Antibody (M1/70.15) [NB600-1327]. Image from a verified customer review.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunocytochemistry-Immunofluorescence-NB600-1327-img0015.jpg)
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) [NB600-1327] - Immunocytochemical/Immunofluorescent analysis in mouse primary microglia. Cells were treated with lysophosphatidic acid (LPA) or LPA and an LPAR5 inhibitor in order to investigate the expression of iNOS after 24 hours. CD11b Antibody (M1/70.15) [NB600-1327] was used in a dilution 1:100 in order to stain primary murine microglia. Cy2 (green) and Cy3 (red) were used as secondary antibodies.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunocytochemistry-Immunofluorescence-NB600-1327-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) - BSA Free [NB600-1327] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody [M1/70.15] conjugated to Alexa Fluor 647 (NB600-1327AF647) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-BSA-Free-Immunocytochemistry-Immunofluorescence-NB600-1327-img0019.jpg)
![Flow Cytometry: CD11b Antibody (M1/70.15) [NB600-1327] - Staining of mouse peritoneal macrophages with Rat anti Mouse CD11b Antibody (M1/70.15) [NB600-1327].](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Flow-Cytometry-NB600-1327-img0004.jpg)
![Flow Cytometry: CD11b Antibody (M1/70.15) [NB600-1327] - Staining of mouse peritoneal macrophages with Rat anti Mouse CD11b Antibody (M1/70.15) [NB600-1327]: RPE - Alexa Fluor 750](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Flow-Cytometry-NB600-1327-img0007.jpg)
![Flow Cytometry: CD11b Antibody (M1/70.15) [NB600-1327] - Staining of mouse peritoneal macrophages using the Alexa Fluor (R) 488 conjugate of CD11b Antibody (M1/70.15) [NB600-1327AF488].](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Flow-Cytometry-NB600-1327-img0014.jpg)
![Western Blot: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Western blot analysis of MDA-MB-231 cells transfected with/without an IL-8 silencer RNA (siIL-8) to evaluate the expression of MUC-1, VCAM-1 (NBP1-28404), and ICAM-1 (NBP2-22541). GAPDH load control was reused for illustrative purposes. Image collected and cropped by CiteAb from the following publication (frontiersin.org/article/10.3389/fimmu.2018.01767/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Western-Blot-NBP2-22541-img0015.jpg "<b>Biological Strategies Validation. </b>Western Blot: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Western blot analysis of MDA-MB-231 cells transfected with/without an IL-8 silencer RNA (siIL-8) to evaluate the expression of MUC-1, VCAM-1 (NBP1-28404), and ICAM-1 (NBP2-22541). GAPDH load control was reused for illustrative purposes. Image collected and cropped by CiteAb from the following publication (frontiersin.org/article/10.3389/fimmu.2018.01767/full), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Frozen: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Staining of frozen rat spleen with Mouse anti Rat CD54.](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Immunohistochemistry-Frozen-NBP2-22541-img0011.jpg)
![Flow Cytometry: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Analysis of CD54 in C6 cells (green) compared to an isotype control (blue).](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Flow-Cytometry-NBP2-22541-img0014.jpg)
![Immunohistochemistry-Paraffin: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Normal biopsies of deparaffinized Mouse kidney tissue.](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Immunohistochemistry-Paraffin-NBP2-22541-img0001.jpg)
![Immunohistochemistry: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Normal biopsies of deparaffinized Mouse lung tissue.](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Immunohistochemistry-NBP2-22541-img0002.jpg)
![Immunohistochemistry-Paraffin: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Normal biopsies of deparaffinized Mouse spleen tissue.](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Immunohistochemistry-Paraffin-NBP2-22541-img0003.jpg)
![Flow Cytometry: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Staining of stimulated rat spleen cells with mouse anti-rat CD54 (Alexa488).](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Flow-Cytometry-NBP2-22541-img0010.jpg)
![Flow Cytometry: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Analysis of CD54 in Ramos cells (green) compared to an isotype control (blue).](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Flow-Cytometry-NBP2-22541-img0012.jpg)
![Flow Cytometry: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Analysis of CD54 in Raji cells (green) compared to an isotype control (blue).](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Flow-Cytometry-NBP2-22541-img0013.jpg)
![Western Blot: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Normalized gene & protein expression of ICAM-1. (A) qPCR results indicated no change in mRNA expression of ICAM-1 at 24 h post-overpressure but a significant increase at 48 h as compared to sham. (B) Subsequent Western blot results confirmed elevated ICAM-1 protein levels at 48 h compared to sham. *p < 0.05, Data are represented as mean ± SEM, gene: n = 7–9/group, protein: n = 8–9/group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30853931), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22541_mouse-monoclonal-icam-1-cd54-antibody-1a29-31020241536370.jpg)
![Western Blot: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Fractionated, compared to single exposure, radiation more profoundly enhanced ICAM-1 expression. Representative (3 independent experiments) Western blot analysis & quantification of ICAM-1 levels in whole-cell lysates from nonirradiated (sham) & irradiated HUVECs 4 h & 24 h after exposure to (a) either five fractions of 2 Gy (5 × 2 Gy) or single exposure to 10 Gy & (b) either five fractions of 2.5 Gy (5 × 2.5 Gy) or single exposure to 12.5 Gy. Fractions delivered at 24-h intervals. beta -actin served as a loading control. c Ectopic expression of ICAM-1 after exposure to 0 Gy, five fractions of 2 Gy, or 10 Gy, as measured by flow cytometry (n = 3). d NF-kappa B activation after 4 h of exposure to 0 Gy, five fractions of 2 Gy, or 10 Gy (n = 2). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32382091), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22541_mouse-monoclonal-icam-1-cd54-antibody-1a29-31020241533490.jpg)
![Western Blot: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Fractionated thoracic irradiation suppressed KLF2 & enhanced ICAM-1 levels in the lung. Quantification of KLF2 (a) & ICAM-1 (b) protein levels & representative Western blot analysis (c) in the lung tissue of mice (n = 6) at 24 h following 5 fractions of 4 Gy at 24 h intervals or single exposure to 20 Gy. beta -actin served as a loading control. KLF2 immunostaining in the lung tissue samples of sham irradiated (d), irradiated (e), & quantitation (f) at 24 h after exposure to 5 fractions of 4 Gy at 24 h intervals or single exposure to 20 Gy. ICAM-1 immunostaining in the lung tissue samples of sham irradiated (g), or irradiated (h), & quantitation (i) at 24 h after exposure to 5 fractions of 4 Gy at 24 h intervals or single exposure to 20 Gy. (n, number of independent experiments performed; a, significant statistical difference between nonirradiated & irradiated groups; b, significant statistical difference between fractionated irradiation & single exposure; *p < 0.05; **p < 0.01; ***p < 0.001). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32382091), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22541_mouse-monoclonal-icam-1-cd54-antibody-1a29-31020241611356.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody [NBP1-71663] - Staining of mouse glioma tissue using CD31/PECAM-1 Antibody (NBP1-71663) at a dilution of 1:2500. Image provided by Dr. Eric Woolf of Dignity Health.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-71663-img0009.jpg "Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody [NBP1-71663] - Staining of mouse glioma tissue using CD31/PECAM-1 Antibody (NBP1-71663) at a dilution of 1:2500. Image provided by Dr. Eric Woolf of Dignity Health.")
![Simple Western: CD31/PECAM-1 Antibody [NBP1-71663] - Image shows a specific band for CD31/PECAM 1 in 0.5 mg/mL of HUVEC lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Simple-Western-NBP1-71663-img0010.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: CD31/PECAM-1 Antibody [NBP1-71663] - 5-HTR1A agonist enhances neovascularization during skin wound healing (excisional punch biopsy model). CD31/PECAM-1 endothelial cell immunohistochemical staining at day 5 (A,B) and day 7 (E,F), image scale bars represented at 50 um. Results were presented as mean +/- SEM (n = 5 images per wound). Two-way ANOVA was performed and significance levels were set at *P < 0.05, **P < 0.01. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/article/10.3389/fphar.2018.01406/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Immunohistochemistry-NBP1-71663-img0012.jpg)
![Western Blot: CD31/PECAM-1 Antibody [NBP1-71663] - Snail and EndMT-related protein expression in lungs in orthotopic murine 4T1 breast cancer model. ag Expression of Snail (see Methods). Levels of CD31/PECAM-1 determined by western blot analysis in pooled (n = 6) samples in control and 4T1 breast cancer-bearing mice from the 1st to 5th week after 4T1 cancer cell inoculation (see Methods). Results presented as fold change vs control sample corresponding to healthy mice. Total protein after transfer was used as loading control Image collected and cropped by Citeab from the following publication (Nitric oxide deficiency and endothelial-mesenchymal transition of pulmonary endothelium in the progression of 4T1 metastatic breast cancer in mice. Breast Cancer Res (2018) licensed under a CC-BY license](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Western-Blot-NBP1-71663-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody [NBP1-71663] - HUVEC cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with CD31/PECAM-1 Antibody at 5 ug/mL overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-71663-img0011.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody [NBP1-71663] - CD31/PECAM-1 Antibody was tested in WeHi cells with Dylight 488 (green) alongside a matched isotype control (black).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Flow-Cytometry-NBP1-71663-img0005.jpg)
![Western Blot: CD31/PECAM-1 Antibody [NBP1-71663] - Detection of CD31 in HUVEC cell lysates.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Western-Blot-NBP1-71663-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Human HeLa cells. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunocytochemistry-Immunofluorescence-NB100-77913-img0015.jpg "Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Human HeLa cells. ICC/IF image submitted by a verified customer review.")
![Western Blot: CD63 Antibody (MEM-259) [NB100-77913] - Immunoblot analysis of CD63, CD81, TSG101, and CD9 protein in LSC-Exo and MSC-Exo. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-020-14344-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Western-Blot-NB100-77913-img0016.jpg)
![Immunohistochemistry-Paraffin: CD63 Antibody (MEM-259) [NB100-77913] - Staining of human spleen (paraffin sections) using anti-CD63 (MEM-259).](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunohistochemistry-Paraffin-NB100-77913-img0018.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Flow Cytometry: CD63 Antibody (MEM-259) [FITC] [NB500-483] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) PE-CyTM5. Image using the FITC form of this antibody.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Staining of human skin fibroblasts with anti-CD63 (MEM-259; green) after co-incubation of living cells with human Transferrin - Dyomics 547 (red); cell nuclei stained with DAPI (blue).](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunocytochemistry-Immunofluorescence-NB100-77913-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Staining of CD63 in human primary fibroblasts using anti-CD63 (MEM-259; green). Actin cytoskeleton was decorated by phalloidin (red) and cell nuclei stained with DAPI (blue).](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunocytochemistry-Immunofluorescence-NB100-77913-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Staining of CD63 in human HeLa cell line using anti-CD63 (MEM-259; green). Actin cytoskeleton was decorated by phalloidin (red) and cell nuclei stained with DAPI (blue).](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunocytochemistry-Immunofluorescence-NB100-77913-img0003.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis using the FITC conjugate of NB100-77913. Staining of peripheral blood lymphocytes from a patient with allergy to bee venom after stimulation with bee venom, stained with anti-human CD63 (MEM-259) FITC.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0006.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) PE.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0009.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) purified, GAM-APC.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0010.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) PerCP-CyTM5.5.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0011.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) PerCP.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0012.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Flow Cytometry: CD63 Antibody (MEM-259) [FITC] [NB500-483] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) Alexa Fluor® 488. Image using the FITC form of this antibody.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0013.jpg)
![Western Blot: CD63 Antibody (MEM-259) - BSA Free [NB100-77913] - Cytokine & checkpoint molecule arrays from plasma exosomes showed a decreased concentration of IFN-gamma , IL-10, IL-13, B7-1, B7-2, & ICOSL in GBM patients in comparison to normal donors. (A) Quantification of IFN-gamma , IL-10, & IL-13 in plasma exosomes from normal donors & grade 4 GBM patients' plasma exosomes (mean ± SEM, n = 4/group, *P < 0.05). (B) Quantification of B7-1, B7-2, & ICOSL in plasma exosomes from normal donors & grade 4 GBM patients' plasma exosomes (mean ± SEM, n = 4/group). (C) Quantification of the immunosuppressive checkpoint & T cell costimulatory homolog protein PD-L1 in plasma exosomes from normal donors & grade 4 GBM patients' plasma exosomes (mean ± SEM, n = 4/group). Interestingly, PD-L1 is found at similar levels in both normal donor & glioma patient plasma exosomes & these findings were confirmed by western blot. Western Blot analysis also shows that exosomal markers Flotillin-1 & CD63 are found universally in plasma exosomes from normal donors (n = 3), glioblastoma (grade 4) patients (n = 4), & grade 3 glioma patients (n = 3), though CD63 expression may be slightly reduced in glioma patients. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31380286), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-77913_mouse-monoclonal-cd63-antibody-mem-259-310202415532072.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using Alexa Fluor (R) 488 conjugate of CD45 antibody (OX-1). Rat Splenocytes were stained with CD45 antibody (OX-1) [NB100-64895] (blue) and a matched isotype control [NBP2-27287] (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0005.jpg "Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using Alexa Fluor (R) 488 conjugate of CD45 antibody (OX-1). Rat Splenocytes were stained with CD45 antibody (OX-1) [NB100-64895] (blue) and a matched isotype control [NBP2-27287] (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.")
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using the FITC conjugate of CD45 antibody (OX-1). Staining of rat spleen cells.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0004.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) - BSA Free [NB100-64895] - Representative sequential gating during flow cytometry analysis of rat non-parenchymal liver cells (n = 4). Cells were labeled with antibodies to SE-1 (NB110-68095AF488), CD31, and CD45 (NB100-64895PE). LSECs were then identified as SE-1-Alexa488+ cells (e), and the biexponential CD45-PE/CD31-APC of events (f) were used to display and select the CD45+ CD31+ subsets of LSECs. FMOs (used for gating), and single antibody staining controls are shown in Additional file. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33246411/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-BSA-Free-Flow-Cytometry-NB100-64895-img0006.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Staining of rat peripheral blood lymphocytes with mouse anti-rat CD45 antibody (OX-1) [NB100-64895].](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0001.jpg)
![Immunohistochemistry: CCR2 Antibody [NBP1-48337] - Localization of CCR1 (binds to CCL8, CCL14, and CCL16), CCR2 (binds to CCL2, CCL8, and CCL16), CCR3 (binds to CCL11), and CXCR3 (binds to CXCL10) in the bovine endometrium and fetal trophoblast obtained from cows in their 18th day of pregnancy. Intensive immunoreactivity was observed in endometrial epithelial cells, glandular epithelial cells, or fetal trophoblast. No positive immunoreactivity was observed in the negative control (Control). Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/18/4/742), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-NBP1-48337-img0017.jpg "Immunohistochemistry: CCR2 Antibody [NBP1-48337] - Localization of CCR1 (binds to CCL8, CCL14, and CCL16), CCR2 (binds to CCL2, CCL8, and CCL16), CCR3 (binds to CCL11), and CXCR3 (binds to CXCL10) in the bovine endometrium and fetal trophoblast obtained from cows in their 18th day of pregnancy. Intensive immunoreactivity was observed in endometrial epithelial cells, glandular epithelial cells, or fetal trophoblast. No positive immunoreactivity was observed in the negative control (Control). Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/18/4/742), licensed under a CC-BY license.")
![Western Blot: CCR2 Antibody [NBP1-48337] - Analysis of CCR2 in rat lysate. Image courtesy of product review submitted by Rasha Elbaz.](http://images.novusbio.com/fullsize/CCR2-Antibody-Western-Blot-NBP1-48337-img0005.jpg)
![Flow Cytometry: CCR2 Antibody - BSA Free [NBP1-48337] - An intracellular stain was performed on U2-OS cells with CCR2 NBP1-48337AF647 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/CCR2-Antibody---BSA-Free-Flow-Cytometry-NBP1-48337-img0020.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human liver cancer using 5 ug/ml concentration of CCR2 antibody. Intense cytoplasmic-membranous immune-staining was observed in the cancerous hepatocytes, whereas the staining was relatively weak in the cells adjacent to the fibrotic areas. [Magnification 40X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0011.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human rectal adenocarcinoma using 5 ug/ml concentration of CCR2 antibody. The cancerous cells in the section developed a uniform but specific CCR2 immunopositivity whereas a weak staining was seen in the tumor stroma cells. [Magnification 40X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0012.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE section of human esophageal squamous cell carcinoma (SCC) using 5 ug/ml concentration of CCR2 antibody. Strong cytoplasmic-membranous immune-staining was observed in SCC cells and a relatively weaker staining was seen in the tumor stroma cells. [Magnification 10X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0013.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human normal kidney using 5 ug/ml concentration of CCR2 antibody. Strong cytoplasmic immunostaining was observed in the various renal cells (especially from tubules/ducts epithelium). The cells of Bowman's capsule depicted a very weak cytoplasmic staining for CCR2 protein. [Magnification 10X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0014.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human normal breast using 5 ug/ml concentration of CCR2 antibody. The breast ductal/acinar epithelial cells showed a strong cytoplasmic-membranous CCR2 immune-positivity, whereas the intra-lobular connective tissue depicted weak staining. [Magnification 40X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0015.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48337] - An intracellular stain was performed on THP-1 cells with CCR Antibody NBP1-48337R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48337-img0016.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48337] - An intracellular stain was performed on THP-1 cells with CCR2 Antibody NBP1-48337 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48337-img0018.jpg)
![Flow Cytometry: CCR2 Antibody - BSA Free [NBP1-48337] - An intracellular stain was performed on U2-OS cells with CCR2 NBP1-48337 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/CCR2-Antibody---BSA-Free-Flow-Cytometry-NBP1-48337-img0019.jpg)
![Western Blot: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Exosome or whole cell lysates (WCL) sample from MDA-MB-231 cells was loaded with 10 ug/lane. 10% SDS-PAGE. CD63 antibody (NBP2-32830) was used for primary antibody: 1:500, 4C, overnight. Image from verified customer review.](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Western-Blot-NBP2-32830-img0020.jpg "Western Blot: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Exosome or whole cell lysates (WCL) sample from MDA-MB-231 cells was loaded with 10 ug/lane. 10% SDS-PAGE. CD63 antibody (NBP2-32830) was used for primary antibody: 1:500, 4C, overnight. Image from verified customer review.")
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Immunofluorescence: - Azide and BSA Free [NBP2-34689] - IF staining of HeLa cells using AF488 labeled CD63 Monoclonal Antibody (MX-49. 129.5) (green). F-actin filaments are labeled with dylight 554 phalloidin (red) Nuclei stained with DAPI (blue).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Immunocytochemistry-Immunofluorescence-NBP2-32830-img0011.jpg)
![Immunohistochemistry-Paraffin: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Formalin-fixed, paraffin-embedded Mouse spleen stained with CD63 Antibody (MX-49.129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Immunohistochemistry-Paraffin-NBP2-32830-img0014.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow cytometric analysis of bead-bound exosomes derived from MCF-7 cells. CD63 Mouse Monoclonal antibody (MX-49.129.5) followed by goat anti-mouse IgG-CF568 (orange); unstained exosomes (gray).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0019.jpg)
![Western Blot: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Western Blot: CD63 Antibody (MX-49.129.5) - Azide and BSA Free [NBP2-34689] - Western blot of human spleen Lysate with CD63 Monoclonal Antibody (IMX-49. 129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Western-Blot-NBP2-32830-img0008.jpg)
![Immunohistochemistry-Paraffin: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Immunohistochemistry-Paraffin: CD63 Antibody (MX-49.129.5) - Azide and BSA Free [NBP2-34689] - Formalin-fixed, paraffin-embedded human prostate carcinoma stained with CD63 Monoclonal Antibody (MX-49. 129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Immunohistochemistry-Paraffin-NBP2-32830-img0009.jpg)
![Immunohistochemistry-Paraffin: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Formalin-fixed, paraffin-embedded human melanoma stained with CD63 Antibody (MX-49.129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Immunohistochemistry-Paraffin-NBP2-32830-img0013.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow Cytometry: CD63 Antibody (MX-49.129.5) - Azide and BSA Free [NBP2-34689] - Flow Cytometry of NIH/3T3 Cells. Black: Cells alone; Green: Isotype Control; Red; PE-labeled CD63 Monoclonal Antibody (MX-49. 129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0010.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow Cytometric staining of CD63 on human PBMC cells. Black: cells alone; Green: Isotype Control; Red: PE-labeled CD63 Monoclonal Antibody (MX-49.129.5).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0015.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow cytometry of MCF-7 cells unstained (gray) or stained with CF488A-labeled CD63 monoclonal antibody (MX-49.129.5) (green).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0016.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow cytometry of bead-bound exosomes derived from MCF-7 cells. Unstained exosomes (gray) or stained with CF488A-labeled CD63 monoclonal antibody (MX-49.129.5) (green)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0017.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow cytometric analysis of MCF-7 cells. CD63 Mouse Monoclonal antibody (MX-49.129.5) followed by goat anti-mouse IgG-CF568 (orange); unstained cells (gray).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561] - Integrin beta 1 (P4C10) antibody was tested in -20 degree MeOH fixed HeLa cells at a 1:200 dilution against DyLight 488 (green). Actin and nuclei were counterstained against Phalloidin 568 (red) and DAPI (blue), respectively.](http://images.novusbio.com/fullsize/Integrin-beta-1-CD29-Antibody-P4C10-Immunocytochemistry-Immunofluorescence-NBP2-36561-img0001.jpg "Immunocytochemistry/Immunofluorescence: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561] - Integrin beta 1 (P4C10) antibody was tested in -20 degree MeOH fixed HeLa cells at a 1:200 dilution against DyLight 488 (green). Actin and nuclei were counterstained against Phalloidin 568 (red) and DAPI (blue), respectively.")
![Flow Cytometry: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561] - An intracellular stain was performed on A431 cells with Integrin beta 1/CD29 [P4C10] Antibody NBP2-36561B (blue) and a matched isotype control (orange). Both antibodies were conjugated to Biotin. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Streptavidin - R-Phycoerythrin Protein (2012-1000, Novus Biologicals).](http://images.novusbio.com/fullsize/Integrin-beta-1-CD29-Antibody-P4C10-Flow-Cytometry-NBP2-36561-img0005.jpg)
![Flow Cytometry: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561]](http://images.novusbio.com/fullsize/Integrin-beta-1-CD29-Antibody-P4C10-Flow-Cytometry-NBP2-36561-img0002.jpg)
![Flow Cytometry: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561] - A surface stain was performed on HeLa cells with Integrin beta 1/CD29 [P4C10] Antibody NBP2-36561PE (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/Integrin-beta-1-CD29-Antibody-P4C10-Flow-Cytometry-NBP2-36561-img0003.jpg)
![Flow Cytometry: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561] - A surface stain was performed on HeLa cells with Integrin beta 1/CD29 [P4C10] Antibody NBP2-36561AF488 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/Integrin-beta-1-CD29-Antibody-P4C10-Flow-Cytometry-NBP2-36561-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561] - Overnight incubation with 1:50 Integrin beta 1/CD29 primary antibody in PBS/BSA 1%, at 4ºC. Green: Integrin beta 1/CD29 Antibody (P4C10), Red: Phalloidin, Blue: DAPI. Image from verified customer review.](http://images.novusbio.com/fullsize/antibody/nbp2-36561_mouse-monoclonal-integrin-beta-1-cd29-antibody-p4c10-immunocytochemistry-immunofluorescence-1462023134549..jpg)
![Immunocytochemistry/Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - CTGF antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CTGF-CCN2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-724-img0004.jpg "Immunocytochemistry/Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - CTGF antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).")
![Immunohistochemistry-Paraffin: CTGF/CCN2 Antibody [NB100-724] - Analysis of a FFPE tissue section of human lymph node using 1:200 dilution of CTGF/CCN2 antibody (NB100-724). The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/CTGF-CCN2-Antibody-Immunohistochemistry-Paraffin-NB100-724-img0005.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Analysis of astrocyte reactivity, the cytoskeleton & migration rate following treatment with TGF-beta 2 & CCN2/CTGF. (A) GFAP immunoreactivity (green) is increased in murine ON astrocytes following TGF-beta 2 & CCN2/CTGF treatment. Nuclei are stained with Dapi (blue) (B) Western Blot experiments analyses of alpha -actinin protein synthesis in murine ON astrocytes after the treatment with 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF & 100 ng/ml CCN2/CTGF for 24 h. Densitometric analyses of Western Blot analyses shows the significant increase in alpha -actinin protein synthesis. Mean value of untreated cells (control) was set at 1. GAPDH was used to normalize protein intensity (n = 4; 50 ng CCN2/CTGF: *p = 0.029; 100 ng CCN2/CTGF: *p = 0.015; unpaired two-tailed t-test). (C) Scratch assay analyses show a significant increased migration rate for murine ON astrocytes after the treatment with ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF & 100 ng/ml CCN2/CTGF for 12 h. Mean value of migration rate of control cells was set to 100% (control: n = 15; TGF-beta 2: n = 12, **p = 0.008; 50 ng/ml CCN2/CTGF: n = 10, *p = 0.001; 100 ng/ml CCN2/CTGF: n = 4, **p = 0.0001). Data represented as mean ± SD. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-31020241683912.jpg)
![Immunohistochemistry: CTGF/CCN2 Antibody [NB100-724] - GFAP expression & synthesis in the ON & ONH in a murine glaucoma model. (A) GFAP immunoreactivity in the glial lamina of 1-month (green, upper panel) & 2 months (green, middle & lower panel) old beta B1-CTGF1 mice compared to WT controls. Immunoreactivity of GFAP not altered in 1-month old TG & WT animals (green, upper panel). 2 month old beta B1-CTGF1 mice showed an increased GFAP immunoreactivity compared to WT control (green, middle panel). Lower panel shows a magnified detail of the middle panel. Nuclei are stained w/ Dapi (blue). (B) Schmatic illustration of the optic nerve. A depicts region in the glial lamina where cross sections obtained. ONH (unmyelinated part) & ON (myelinated part) used for molecular analysis. (C) Quantification of immunohistochemical staining of GFAP in the glial lamina is not altered in 1 month old TG & WT animals (WT: n = 5; TG: n = 4). GFAP immunoreactivity is increased in 2 month old TG animals compared to WT littermates (WT: n = 10, TG: n = 13; *p = 0.039; two-tailed t-test compared to oretical mean of 1 (normalized control)). Mean value of WT animals (control) set at 1. (D) RT-PCR analyses revealed no alteration in the Gfap mRNA expression in the ON of 1-month (WT: n = 7; TG: n = 5) & 2 month old beta B1-CTGF1 mice (WT: n = 15; TG: n = 16) compared to WT controls. In the ONH the Gfap mRNA expression is increased in the 2 month old TG compared to WT animals (WT: n = 6, TG: n = 5; *p = 0.04). The mRNA expression of Gfap is not altered in 1 month old animals (WT: n = 6, TG: n = 5). Mean value of WT animals (control) set at 1. RPL32 used to normalize mRNA expression. Data represented as mean ± SEM. PRL, Prelaminar region; PSL, Postlaminar region; ON, optic nerve; ONH, optic nerve head. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415523931.jpg)
![Immunohistochemistry: CTGF/CCN2 Antibody [NB100-724] - GFAP expression & synthesis in the ON & ONH in a murine glaucoma model. (A) GFAP immunoreactivity in the glial lamina of 1-month (green, upper panel) & 2 months (green, middle & lower panel) old beta B1-CTGF1 mice compared to WT controls. Immunoreactivity of GFAP not altered in 1-month old TG & WT animals (green, upper panel). 2 month old beta B1-CTGF1 mice showed an increased GFAP immunoreactivity compared to WT control (green, middle panel). Lower panel shows a magnified detail of the middle panel. Nuclei are stained w/ Dapi (blue). (B) Schmatic illustration of the optic nerve. A depicts region in the glial lamina where cross sections obtained. ONH (unmyelinated part) & ON (myelinated part) used for molecular analysis. (C) Quantification of immunohistochemical staining of GFAP in the glial lamina is not altered in 1 month old TG & WT animals (WT: n = 5; TG: n = 4). GFAP immunoreactivity is increased in 2 month old TG animals compared to WT littermates (WT: n = 10, TG: n = 13; *p = 0.039; two-tailed t-test compared to oretical mean of 1 (normalized control)). Mean value of WT animals (control) set at 1. (D) RT-PCR analyses revealed no alteration in the Gfap mRNA expression in the ON of 1-month (WT: n = 7; TG: n = 5) & 2 month old beta B1-CTGF1 mice (WT: n = 15; TG: n = 16) compared to WT controls. In the ONH the Gfap mRNA expression is increased in the 2 month old TG compared to WT animals (WT: n = 6, TG: n = 5; *p = 0.04). The mRNA expression of Gfap is not altered in 1 month old animals (WT: n = 6, TG: n = 5). Mean value of WT animals (control) set at 1. RPL32 used to normalize mRNA expression. Data represented as mean ± SEM. PRL, Prelaminar region; PSL, Postlaminar region; ON, optic nerve; ONH, optic nerve head. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415535150.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Analyses of ECM components in murine ON astrocytes following treatment w/ TGF-beta 2 & CCN2/CTGF. (A) Immunocytochemical staining against fibronectin (green, upper panel) showed a markedly increase following the treatment w/ 1 ng/ml TGF-beta 2 or 50 ng/ml CCN2/CTGF. Immunocytochemical staining against tropoelastin (green, lower panel) showed a pronounced increase after treatment w/ 1 ng/ml TGF-beta 2 or 50 ng/ml CCN2/CTGF. Nuclei stained w/ Dapi (blue). (B) Real-time RT-PCR analyses shows an intense upregulation of collagen 3 alpha 1, tropoelastin & fibronectin mRNA in murine ON astrocytes after treatment w/ 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF or 100 ng/ml CCN2/CTGF for 24 h compared to untreated control cells (collagen 3 alpha 1: n = 3; TGF-beta 2 ***p = 0.0000004, 50 ngCTGF **p = 0.005, 100ngCTGF **p = 0.008; fibronectin: n = 6, TGF-beta 2 *p = 0.00004, 50 ng CTGF *p = 0.016, 100 ngCTGF *p = 0.05; elastin: n = 5, TGF-beta 2 *p = 0.026, 50 ng CTGF *0.04, 100 ng CTGF *p = 0.03). mRNA expression normalized to Gnb2l & mean value of control cells set at 1. (C) Western Blot analysis show an increase in protein synthesis of collagen 3 alpha 1, elastin & fibronectin in murine ON astrocytes after treatment w/ 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF or 100 ng/ml CCN2/CTGF for 24 h compared to untreated control cells (collagen 3 alpha 1: n = 3, TGF-beta 2 *p = 0.03, 100 ngCTGF **p = 0.009; fibronectin: n = 5, **p = 0.005, 50 ngCTGF **p = 0.006, 100 ng CTGF *p = 0.02; tropoelastin: n = 5, TGF-beta 2 ***p = 0.0004, 50 ngCTGF **p = 0.002, 100 ngCTGF ***p = 0.00001). GAPDH & alpha -tubulin used to normalize protein synthesis & mean value of control cells set at 1. Right panel shows representative Western Blots for all three proteins. Data represented as mean ± SD. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415532092.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Increasing substratum stiffness causes alterations in murine ON astrocyte reactivity, actin cytoskeleton & CCN2/CTGF level. (A) Filamentous actin labeled by phalloidin (red, upper panel) is increased when murine ON astrocytes were cultured on substrates with higher stiffness (30 kPa, 60 kPa) compared to softer control (10 kPa). Increasing substratum stiffness leads to an enhanced formation of actin stress fibers. Immunoreactivity of CCN2/CTGF (green, middle panel) is markedly increased when murine ON astrocytes were grown on substrates with higher stiffness (30, 60 kPa) compared to softer control (10 kPa). Murine ON astrocytes show an enhanced GFAP protein synthesis (green, lower panel) when cultured on 30 or 60 kPa compared to 10 kPa. Nuclei were stained with Dapi (blue). (B) CCN2/CTGF protein synthesis is significantly increased in murine ON astrocytes grown on 60 kPa compared to 10 kPa (10 kPa: n = 5; 30 kPa: n = 5; 60 kPa: n = 5; *p = 0.04; unpaired two-tailed t-test). (C) Protein synthesis of GFAP (10 kPa: n = 6; 30 kPa: n = 6, **p = 0.005; 60 kPa: n = 4, *p = 0.04; unpaired two-tailed t-test) show an enhanced reactivity of murine ON astrocytes cultured on 30 kPa or 60 kPa compared to 10 kPa control. (D) Vimentin protein synthesis is significantly increased in murine ON astrocytes cultured on 60 kPa compared to 10 kPa (10 kPa: n = 4; 30 kPa: n = 4; 60 kPa: n = 3 ***p = 0.00002). Protein synthesis was normalized to alpha -tubulin & mean value of control (10 kPa) was set at 1. Data represented as mean ± SEM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-31020241612698.jpg)
![Western Blot: LYVE-1 Antibody [NB100-725] - Western Blot: [NB100-725] - Total protein from human stomach, lymph node and placenta was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-LYVE1 in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Western-Blot-NB100-725-img0027.jpg "Western Blot: LYVE-1 Antibody [NB100-725] - Western Blot: [NB100-725] - Total protein from human stomach, lymph node and placenta was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-LYVE1 in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry-Paraffin: LYVE-1 Antibody [NB100-725] - Analysis using the DyLight 488 conjugate of NB100-725. Staining of LYVE1 in paraffin embedded MDA-MB-231 breast cancer orthotopic transplantation tissue. Image courtesy of product review submitted by Luana Schito.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-Paraffin-NB100-725-img0028.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB100-725] - Detection of LYVE1 in endothelial cells of human lung blood vessels using NB100-725. Note presence of RBCs within vessel lumen.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-NB100-725-img0011.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - Analysis using the DyLight 488 conjugate of NB100-725. Unlabeled control with labeled samples of cells dissociated mechanically and enzymatically from human skin. Image provided via product review by Patricia Redondo.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0024.jpg)
![Western Blot: LYVE-1 Antibody [NB100-725] - Analysis of extracts from A549 cells using LYVE1 antibody (NB100-725, 1:100). Image from verified customer review.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Western-Blot-NB100-725-img0018.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - LYVE1 antibody was tested at 1:400 in A549 cells using an Alexa Fluor 488 secondary (shown in green) alongside unstained cells (shown in red).](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0016.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - An intracellular stain was performed on A549 cells with LYVE-1 Antibody NB100-725 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0031.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB100-725] - Detection of LYVE1 in endothelial cells of human bladder vasculature using NB100-725.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-NB100-725-img0012.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB100-725] - Detection of LYVE1 in endothelial cells of human lung blood vessels using NB100-725.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-NB100-725-img0013.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - Analysis using the Alexa Fluor (R) 488 conjugate of NB100-725. Staining of LYVE1 in human dissociated skin lyve1+ using AF488 conjugated anti-LYVE1 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0023.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - An intracellular stain was performed on A549 cells with LYVE-1 Antibody NB100-725G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Dylight 488.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0029.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - An intracellular stain was performed on K562 cells with LYVE-1 Antibody NB100-725C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0030.jpg)
![Western Blot: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Analysis of human tonsil (1), human spleen (2), and human lymph node (3) tissue using CD162 antibody at a concentration of 2 ug/ml.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Western-Blot-NB100-78039-img0006.jpg "Western Blot: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Analysis of human tonsil (1), human spleen (2), and human lymph node (3) tissue using CD162 antibody at a concentration of 2 ug/ml.")
![Immunohistochemistry-Paraffin: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Human tonsil tissue stained with PSGL-1/CD162 Antibody (HECA-452) at 5ug/mL, and Leica Refine DAB kit. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PSGL-1-CD162-Antibody-HECA-452-Immunohistochemistry-Paraffin-NB100-78039-img0014.jpg)
![Flow (Cell Surface): PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD3+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and a matched isotype control NBP2-31379. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody [F0101B, R&D Systems]. A co-stain was performed using CD3 antibody NBP2-25186APC.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cell-Surface-NB100-78039-img0008.jpg)
![Immunohistochemistry-Paraffin: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - IHC analysis of formalin-fixed paraffin-embedded tissue section of human breast adenocarcinoma using CLA antibody (clone HECA-452) at 5 ug/ml concentration. The antibody generated a membrane-cytoplasmic staining in the cancerous cells of breast adenocarcinoma. Note:- Besides lymphocytes, CLA has been shown to be present on cells of normal endometrium as well as breast cancer tissues (PMID 19625313 and 22970241).](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Immunohistochemistry-Paraffin-NB100-78039-img0004.jpg)
![Flow Cytometry: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Human peripheral blood lymphocytes stained with purified HECA-452, followed by anti-mouse IgG FITC](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cytometry-NB100-78039-img0005.jpg)
![Flow (Cell Surface): PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD14+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and a matched isotype control NBP2-31379. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by rat-Dylight 488 conjugated secondary antibody. A co-stain was performed using CD14 antibody NB100-77758AF488.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cell-Surface-NB100-78039-img0007.jpg)
